Skip to content
Screener

G&A at other companies

Immunome logo
ImmunomeIMNM
$12.95M+21.1%
Perspective Therapeutics logo
Perspective TherapeuticsCATX
$7.8M+1.1%
CTO
Citius Oncology, Inc.CTOR
$23.63M+953%
Lumexa Imaging Holdings, Inc. logo
Lumexa Imaging Holdings, Inc.LMRI
$20.34M+16.3%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
$1.74M+10.1%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$12.82M-13.2%

Other financials

Income statement

See full
Revenue$388.2M+2.7%
Gross profit$241.9M+0.4%
Operating income$100.2M+13.9%
Net income$75.0M-4.7%
EPS (diluted)$1.11-0.9%

Balance sheet

See full
Cash & equivalents$595.0M-14.7%
Total debt$626.8M+1.5%
Total equity$1.3B+12.4%
Total assets$2.4B+14.1%

Cash flow

See full
Operating cash flow$92.2M+5.9%
CapEx$2.3M-70.7%
Free cash flow$89.9M+13.5%

Valuation

See full
Market cap$6.6B+83.8%
Enterprise value$6.63B+88.9%
P/E24×+11.3×
P/S4.2×+1.9×

Profitability

See full
Gross margin60.1%-3.6pp
Operating margin19.4%-9.4pp
Net margin17.7%-0.9pp
FCF margin24.9%-6.6pp

Returns & leverage

See full
Return on equity22.2%-3.6pp
Debt / equity0.5×-0.1×
Current ratio3.1×-1.2×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Lantheus Holdings’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336795
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gross profit241,855241,011472,777478,711
Operating expenses
Sales and marketing82,80541,041135,48983,544
General and administrative20,63366,51578,166123,331
Research and development38,20245,48977,58181,803
Total operating expenses141,640153,045291,236288,678
Operating income100,21587,966181,541190,033
Interest expense4,9154,9179,7799,721

Item 1. Financial Statements

FAQ

What is Lantheus Holdings's G&A?
Lantheus Holdings (LNTH) reported G&A of $20.63M in Q2 2026.
How has Lantheus Holdings's G&A changed year-over-year?
Lantheus Holdings's G&A decreased by 69.0% year-over-year, from $66.52M to $20.63M.
What is the long-term trend for Lantheus Holdings's G&A?
Over 4 years (2021 to 2025), Lantheus Holdings's G&A has grown at a 16.3% compound annual growth rate (CAGR), from $150.4M to $275.12M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Lantheus Holdings's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude